Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.30
NAS:MNKD's Cash-to-Debt is ranked lower than
92% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:MNKD: 0.30 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:MNKD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.31 Max: No Debt
Current: 0.3
Equity-to-Asset -2.33
NAS:MNKD's Equity-to-Asset is ranked lower than
99% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:MNKD: -2.33 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:MNKD' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.48  Med: -0.8 Max: 0.87
Current: -2.33
-2.48
0.87
Interest Coverage 3.99
NAS:MNKD's Interest Coverage is ranked lower than
92% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:MNKD: 3.99 )
Ranked among companies with meaningful Interest Coverage only.
NAS:MNKD' s Interest Coverage Range Over the Past 10 Years
Min: 3.64  Med: 3.64 Max: 3.64
Current: 3.99
Piotroski F-Score: 4
Altman Z-Score: -37.56
Beneish M-Score: 4531.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 38.07
NAS:MNKD's Operating Margin % is ranked higher than
95% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:MNKD: 38.07 )
Ranked among companies with meaningful Operating Margin % only.
NAS:MNKD' s Operating Margin % Range Over the Past 10 Years
Min: -3073570  Med: -350481.86 Max: 38.49
Current: 38.07
-3073570
38.49
Net Margin % 75.50
NAS:MNKD's Net Margin % is ranked higher than
97% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:MNKD: 75.50 )
Ranked among companies with meaningful Net Margin % only.
NAS:MNKD' s Net Margin % Range Over the Past 10 Years
Min: -2931900  Med: -402755.43 Max: 71.91
Current: 75.5
-2931900
71.91
ROA % 128.78
NAS:MNKD's ROA % is ranked higher than
99% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:MNKD: 128.78 )
Ranked among companies with meaningful ROA % only.
NAS:MNKD' s ROA % Range Over the Past 10 Years
Min: -141.48  Med: -70.42 Max: 107.65
Current: 128.78
-141.48
107.65
ROC (Joel Greenblatt) % 323.60
NAS:MNKD's ROC (Joel Greenblatt) % is ranked higher than
97% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:MNKD: 323.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:MNKD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -285.89  Med: -95.4 Max: 258.42
Current: 323.6
-285.89
258.42
GuruFocus has detected 4 Warning Signs with MannKind Corp $NAS:MNKD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:MNKD's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

MNKD Guru Trades in Q2 2016

Paul Tudor Jones 103,325 sh (-0.05%)
» More
Q3 2016

MNKD Guru Trades in Q3 2016

Paul Tudor Jones 103,325 sh (unchged)
» More
Q4 2016

MNKD Guru Trades in Q4 2016

Joel Greenblatt 90,068 sh (New)
Paul Tudor Jones 103,325 sh (unchged)
» More
Q1 2017

MNKD Guru Trades in Q1 2017

Joel Greenblatt 18,825 sh (+4.50%)
Paul Tudor Jones 20,665 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MNKD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CDTX, AMEX:MTNB, OTCPK:EGRN, NAS:FATE, NAS:OMED, OTCPK:CNBX, NAS:VVUS, NAS:CBMG, OTCPK:IPIX, NAS:VSTM, NAS:PTI, NAS:DRNA, OTCPK:HPPI, NAS:REPH, AMEX:OCX, NAS:VTL, NAS:AXSM, NAS:GNCA, NAS:ARWR, NAS:SBPH » details
Traded in other countries:NNFN.Germany,
Headquarter Location:USA
MannKind Corp is a development stage biotech firm. It is engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and cancer.

MannKind is a biotech firm focused on researching treatments for diabetes and cancer. Its lead product candidate, Afrezza, is a rapid-acting inhaled insulin that has been approved in the U.S. and partnered with Sanofi for global commercialization. MannKind's early-stage pipeline includes testing its proprietary inhalation technology in other diabetes treatments and developing several early-stage immunotherapy and oncology therapeutics.

Top Ranked Articles about MannKind Corp

Steven Binder Joins MannKind as Chief Financial Officer
Patrick McCauley Joins MannKind as Chief Commercial Officer
MannKind Engages Locust Walk to Explore Strategic Options for MannKind’s Non-insulin Technosphere-based Pipeline Candidates
MannKind and Biomm Enter Into Distribution Agreement for Afrezza in Brazil
MannKind Provides Update on Senior Management
MannKind and One Drop to collaborate on delivering better health outcomes for people with diabetes
MannKind Corporation to Hold 2017 First Quarter Financial Results Conference Call on May 10, 2017
MannKind Corporation and Charles Mattocks Announce “REVERSED”-America’s First Docu-Series Tackling Diabetes
VALENCIA, Calif. and TAMPA, Fla., March 08, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation and Bella & Elle Media LLC announce MannKind’s sponsorship of “Reversed,” a production series aimed at educating the show’s participants and viewing audience about the effects of poorly managed diabetes and its impact on their lives.  â€œReversed” will air on Discovery Life Channel in the summer of 2017.   
“Reversed” was created by Celebrity Chef and Diabetes Advocate, Charles Mattocks.  The award-winning producer and bestselling author will host “Reversed,” as it follows the lives of individuals affected by diabetes and their struggle to change their diet, exercise and mindset about the disease.  “Reversed” will feature experts such as diabetes educators, endocrinologists, therapists, nutritionists, and trainers, as well as celebrity guests who are also living with diabetes, to help encourage the contestants.Charles Mattocks, nephew of legendary Bob Marley, said, “My uncle made an impact on the world through music and my vision is to impact health. 'Reversed' is about changing the behavior of those with diabetes. I am excited that MannKind has joined 'Reversed' in our mission." Michael Castagna, Chief Commercial Officer of MannKind Corporation, added, “MannKind is continually seeking platforms to increase awareness around the challenges, opportunities and success people living with diabetes encounter on a daily basis.  Mr. Mattock’s educational platforms, which have been featured on CNN, Dr. Oz and The Today Show, showcase the strength and determination of people fighting to make their lives better as they fight diabetes.  We are excited to be associated with Mr. Mattock’s continuing efforts to educate the public.”   ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes.  MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.ABOUT BELLA & ELLE MEDIA LLC
For more information visit www.reversedyourhealth.com and sign up for updates on the show and the other work being done to help educate and empower individuals affected by this disease. Questions about the movement that is REVERSED can be directed to Charles Mattocks at [email protected].
MannKind Contact:
Rose Alinaya
SVP, Finance
661-775-5300
[email protected]

Bella & Elle Media LLC Contact:
Charles Mattocks
201-755-5386
[email protected]

Read more...
MannKind Corporation Announces Upcoming Events

- 29th Annual ROTH Conference on March 13, 2017 -
- 2016 Fourth Quarter and Full Year Financial Results Conference Call on March 16, 2017 - VALENCIA, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) announced two upcoming events: Presenting at 29th Annual ROTH Conference on Monday, March 13, 2017 at 5:00 pm (PDT) at the Ritz Carlton in Dana Point, California.

To view and listen to the conference webcast, visit MannKind's website at http://www.mannkindcorp.com and click on the "29th Annual ROTH Conference" link in the Webcast section of News & Events.

Release of 2016 fourth quarter and full year financial results on Thursday, March 16, 2017 and management to host a conference call to discuss financial results and other Company developments at 5:00 pm (EDT) on March 16, 2017.

To view and listen to the earning call webcast, visit MannKind's website at http://www.mannkindcorp.com and click on the "Q4 2016 MannKind Earnings Conference Call" link in the Webcast section of News & Events. To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 44096370.

A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4409 6370#. A replay will also be available on MannKind's website for 14 days.

As with past calls, the Company will take live questions from covering analysts.  Stockholders who wish to submit questions in advance of the call should email them to [email protected]. About MannKind Corporation MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes.  MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact:
Rose Alinaya 
SVP Finance
661-775-5300
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 0.97
MNKD's PE Ratio is ranked higher than
97% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. MNKD: 0.97 )
Ranked among companies with meaningful PE Ratio only.
MNKD' s PE Ratio Range Over the Past 10 Years
Min: 0.6  Med: 1.29 Max: 2.87
Current: 0.97
0.6
2.87
PE Ratio without NRI 0.97
MNKD's PE Ratio without NRI is ranked higher than
97% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. MNKD: 0.97 )
Ranked among companies with meaningful PE Ratio without NRI only.
MNKD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.6  Med: 1.29 Max: 2.87
Current: 0.97
0.6
2.87
Price-to-Owner-Earnings 4.53
MNKD's Price-to-Owner-Earnings is ranked higher than
93% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. MNKD: 4.53 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MNKD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.79  Med: 5.05 Max: 7.74
Current: 4.53
2.79
7.74
PS Ratio 0.71
MNKD's PS Ratio is ranked higher than
98% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. MNKD: 0.71 )
Ranked among companies with meaningful PS Ratio only.
MNKD' s PS Ratio Range Over the Past 10 Years
Min: 0.43  Med: 15500 Max: 79400
Current: 0.71
0.43
79400
EV-to-EBIT 1.60
MNKD's EV-to-EBIT is ranked higher than
87% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. MNKD: 1.60 )
Ranked among companies with meaningful EV-to-EBIT only.
MNKD' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.5  Med: -3.8 Max: 3.2
Current: 1.6
-19.5
3.2
EV-to-EBITDA 1.56
MNKD's EV-to-EBITDA is ranked higher than
88% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. MNKD: 1.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNKD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.3  Med: -4.3 Max: 3.1
Current: 1.56
-21.3
3.1
Current Ratio 0.60
MNKD's Current Ratio is ranked lower than
93% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. MNKD: 0.60 )
Ranked among companies with meaningful Current Ratio only.
MNKD' s Current Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.31 Max: 12.24
Current: 0.6
0.12
12.24
Quick Ratio 0.56
MNKD's Quick Ratio is ranked lower than
91% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. MNKD: 0.56 )
Ranked among companies with meaningful Quick Ratio only.
MNKD' s Quick Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.31 Max: 12.24
Current: 0.56
0.12
12.24
Days Inventory 24.72
MNKD's Days Inventory is ranked higher than
86% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. MNKD: 24.72 )
Ranked among companies with meaningful Days Inventory only.
MNKD' s Days Inventory Range Over the Past 10 Years
Min: 8.49  Med: 17.88 Max: 27.26
Current: 24.72
8.49
27.26
Days Sales Outstanding 0.90
MNKD's Days Sales Outstanding is ranked higher than
99% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. MNKD: 0.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNKD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.45  Med: 4692.86 Max: 30331.5
Current: 0.9
64.45
30331.5
Days Payable 13.39
MNKD's Days Payable is ranked lower than
82% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. MNKD: 13.39 )
Ranked among companies with meaningful Days Payable only.
MNKD' s Days Payable Range Over the Past 10 Years
Min: 23.78  Med: 55.86 Max: 87.94
Current: 13.39
23.78
87.94

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.00
MNKD's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. MNKD: -9.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNKD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.3  Med: -39.35 Max: -8
Current: -9
-58.3
-8

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % 62.50
MNKD's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. MNKD: 62.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNKD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -527.6  Med: -20.7 Max: 80.6
Current: 62.5
-527.6
80.6

More Statistics

Revenue (TTM) (Mil) $177.77
EPS (TTM) $ 1.34
Beta2.81
Short Percentage of Float29.89%
52-Week Range $0.67 - 5.10
Shares Outstanding (Mil)101.01

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -0.45 -0.50 -0.30
EPS without NRI ($) -0.45 -0.50 -0.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MNKD

Headlines

Articles On GuruFocus.com
Steven Binder Joins MannKind as Chief Financial Officer Jul 17 2017 
Patrick McCauley Joins MannKind as Chief Commercial Officer Jul 12 2017 
MannKind Engages Locust Walk to Explore Strategic Options for MannKind’s Non-insulin Technosphe Jun 05 2017 
MannKind and Biomm Enter Into Distribution Agreement for Afrezza in Brazil May 31 2017 
MannKind Provides Update on Senior Management May 30 2017 
MannKind and One Drop to collaborate on delivering better health outcomes for people with diabetes May 04 2017 
MannKind Corporation to Hold 2017 First Quarter Financial Results Conference Call on May 10, 2017 Apr 28 2017 
MannKind Corporation and Charles Mattocks Announce “REVERSED”-America’s First Docu-Se Mar 08 2017 
MannKind Corporation Announces Upcoming Events Mar 07 2017 
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against MannKind Corp. Jan 20 2016 

More From Other Websites
Steven Binder Joins MannKind as Chief Financial Officer Jul 17 2017
Today's Research Reports on Stocks to Watch: Mannkind Corporation and AstraZeneca Jul 14 2017
Options Traders Expect Huge Moves in MannKind (MNKD) Stock Jul 13 2017
Patrick McCauley Joins MannKind as Chief Commercial Officer Jul 12 2017
MannKind Renegotiates Near-Term Maturities with Deerfield Jun 29 2017
MannKind Draws Remaining Funds under Mann Group Loan Arrangement Jun 29 2017
Is the Options Market Predicting a Spike in MannKind (MNKD) Stock? Jun 16 2017
3 Surging Penny Stocks You'll Want Nothing to Do With Jun 09 2017
MannKind Engages Locust Walk to Explore Strategic Options for MannKind’s Non-insulin... Jun 05 2017
MannKind and Biomm Enter Into Distribution Agreement for Afrezza in Brazil May 31 2017
MannKind Provides Update on Senior Management May 30 2017
MannKind Corporation (MNKD) Catches Eye: Stock Jumps 7% May 30 2017
Short Sellers Raise the Stakes in Major Biotechs May 25 2017
Edited Transcript of MNKD earnings conference call or presentation 10-May-17 9:00pm GMT May 17 2017
Here's Why MannKind Corporation Stock Is Tanking Today May 11 2017
Implied Volatility Surging for MannKind Corporation (MNKD) Stock Options May 11 2017
Today's Research Reports on Stocks to Watch: MannKind and Neuralstem May 11 2017
MannKind reports 1Q loss May 10 2017
MannKind Corporation Reports 2017 First Quarter Financial Results May 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}